Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dr Eoghan Mulholland has received the prestigious Lee Placito Research Fellowship in Gastrointestinal Cancer. Eoghan will use this 3-year position to research cell interactions in colorectal cancers.

Eoghan Muholland

Dr Eoghan Mulholland, Postdoctoral Research Scientist in Cancer Genetics at the Wellcome Centre for Human Genetics and member of Somerville College has recently been awarded the Lee Placito Research Fellowship in Gastrointestinal Cancer.

Colorectal cancer (CRC) is currently the 2nd most common cause of cancer death in the UK. To date, research tells us that it isn’t just the genetic defects in the cancer cells that influences how a cancer behaves, but also how the supporting (stromal) and immune cells interact with it. Currently we don’t fully understand how these ‘cell conversations’ initiate and develop but using cutting-edge research methodologies we can have the opportunity to ‘eavesdrop’. Using the Lee Placito Fellowship, Dr Mulholland  will focus in on these cellular exchanges to better understand how cancer cells, stromal cells and immune cells interact with each other across both human tissue and in Genetically Engineered Mouse Models. Through better understanding of this we can then hope to influence how the cells conversation, change the CRC dynamics, and ultimately improve treatment.

On receiving this Fellowship, Dr Mulholland commented:Using the Lee Placito Fellowship, I will focus in on the ‘cell conversations’ between cancer cells, stromal cells and immune cells. Through better understanding of this we can then hope to influence how the cells communicate, change the colorectal cancer dynamics, and ultimately improve treatment.’

Find out more about the Lee Placito Research Fellowship

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.